Carbapenem-resistant Escherichia coli resistant to ceftazidime-avibactam: The need for a commercially available testing product.

Am J Health Syst Pharm

Pharmacy DepartmentAmita Health-Alexian Brothers Health SystemElk Grove Village, IL.

Published: July 2016

Download full-text PDF

Source
http://dx.doi.org/10.2146/ajhp160041DOI Listing

Publication Analysis

Top Keywords

carbapenem-resistant escherichia
4
escherichia coli
4
coli resistant
4
resistant ceftazidime-avibactam
4
ceftazidime-avibactam commercially
4
commercially testing
4
testing product
4
carbapenem-resistant
1
coli
1
resistant
1

Similar Publications

Introduction The antimicrobial resistance of is variable and is influenced by both geographic location and regional antibiotic use. The overuse of antibiotics, especially in hospitalised patients, suppresses the growth and persistence of drug-resistant bacteria. This study aimed to detect the prevalence of carbapenem-resistant and the genes responsible for the resistance.

View Article and Find Full Text PDF

[Clinical characteristics and prognostic analysis of carbapenem-resistant Enterobacteriaceae bloodstream infections in patients with hematologic diseases].

Zhonghua Xue Ye Xue Za Zhi

November 2024

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 30l600, China.

This study aimed to analyze the clinical and molecular characteristics of carbapenem-resistant Enterobacteriaceae (CRE) bloodstream infection (BSI) in patients with hematological diseases and to explore prognostic risk factors. This retrospective study included patients with hematologic diseases with CRE BSI at the Institute of Hematology and Blood Diseases Hospital from January 2015 to December 2022. The clinical features, carbapenemase test results, antimicrobial treatments, and outcomes were analyzed.

View Article and Find Full Text PDF

Carbapenemase producing (CPEs) represent a group of multidrug resistant pathogens for which few, if any, therapeutics options remain available. CPEs generally harbor plasmids that encode resistance to last resort carbapenems and many other antibiotics. We previously performed a high throughput screen to identify compounds that can disrupt the maintenance and replication of resistance conferring plasmids through use of a synthetic screening plasmid introduced into K-12 cells.

View Article and Find Full Text PDF

Gastrointestinal carriage of antimicrobial-resistant bacteria, especially carbapenemase-producing Enterobacterales (CPE), presents a critical public health threat globally. However, in many resource-constrained countries, epidemiological data on CPE is limited. Here, we assessed gastrointestinal carriage and associated factors of CPE among inpatient and outpatient children (≤ 5 years).

View Article and Find Full Text PDF

Cefiderocol (FDC), a siderophore-cephalosporin conjugate, is the newest option for treating infection with carbapenem-resistant gram-negative bacteria. We identified a novel mechanism contributing to decreased FDC susceptibility in Klebsiella pneumoniae clinical isolates. The mechanism involves 2 coresident plasmids: pKpQIL, carrying variants of bla carbapenemase gene, and pKPN, carrying the ferric citrate transport (FEC) system.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!